Pfizer Inc. (PFE)
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
Dividend investors have had plenty to cheer in 2026. Pfizer (NYSE:PFE | PFE Price Prediction) is up 19.3% year to date, Chevron (NYSE:CVX) has surged 38.76%, and AbbVie (NYSE:ABBV) has added 19.16%.
Yield Hunters Are Swarming This 6.3%-Dividend Stock—And Big-League Hedge Funds are Quietly Buying the Dip
Big-league hedge funds have been taking interest in shares of Pfizer (NYSE:PFE | PFE Price Prediction) of late, with recent 13F filings revealing significant buying activity among the smart money crowd.
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far.
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.
Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff
Pfizer remains a cautious Buy, trading near intrinsic value with an expected 10% annual return, primarily from its high dividend yield. PFE faces significant headwinds: a looming patent cliff, a stretched balance sheet, and questions about the sustainability of its dividend and growth prospects. Management projects high single-digit revenue CAGR post-2028, driven by acquisitions, pipeline progress, and aggressive cost-saving initiatives, though analysts remain skeptical.
Valneva: The Lyme Royalty Transition Changes The Earnings Model
Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and milestone model, anchored by its Lyme disease partnership with Pfizer. Recent financials were impacted by IXCHIQ-related charges, but restructuring is improving the expense base and cash runway, with about three years of funding at current burn rates. Pfizer's Lyme vaccine candidate, with 73% efficacy and EMA validation, positions VALN for significant royalty and milestone income if approved and successfully commercialized.
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug was taken off the market in 2021.
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.
Pfizer's Pipeline Could Change Everything
Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attractive valuation supporting upside potential. PFE's Q2 2026 results showed 1% operational revenue growth and a 12% EPS beat, driven by solid non-COVID sales and a robust growth portfolio. Cost Realignment Program expansions are set to deliver $7.2B in net savings by 2026 and another $2.5B through 2029, enhancing future earnings.
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.
Monster insider trading alert for Pfizer stock
As Pfizer Inc. (NYSE: PFE) stock gained over 5% this week fueled by its strong second quarter 2026 earnings report, Finbold has observed its increased insider trading.
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
